Neither the need for unplanned postoperative visits for complications nor the incidence of visually disturbing cystoid macular edema (CME) was significantly reduced by adding a topical NSAID to postoperative topical steroid treatment, finds a recent study.
The glaucoma device market is expected to grow at three to four times the rate of the refractive and cataract surgery and the IOL markets over the next few years, Dr. Singh said.
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: MultiMedia Healthcare
535 Connecticut Avenue, Suite 300
Norwalk, CT, 06854, USA
